V3R 6 Activators
V3R 6 Activators are a class of chemical compounds that indirectly stimulate the functional activity of V3R 6 by engaging with various intracellular signaling pathways. Forskolin, Isoproterenol, Rolipram, IBMX, and Epinephrine all operate through mechanisms that lead to an increase in cAMP levels. The elevation of this messenger molecule activates protein kinase A, which can phosphorylate V3R 6, enhancing its activity. Similarly, PGE2, by interacting with specific prostaglandin receptors, leads to elevated cAMP and subsequent PKA activation, with the same potential for phosphorylating and activating V3R 6. Anisomycin, though a less direct actor, stimulates the JNK signaling pathway, which can ultimately promote a cellular environment conducive to the enhancement of V3R 6's activity. PMA, as a direct activator of protein kinase C, helps in the phosphorylation cascade that might enhance the activity of V3R 6.
The activators continue with compounds like Sildenafil, Vardenafil, and Zaprinast, which inhibit phosphodiesterase 5, thereby preventing the breakdown of cGMP. This accumulation of cGMP could engage cGMP-dependent protein kinases, which may then enhance the activity of V3R 6. L-arginine's role as a substrate for nitric oxide synthesis further contributes to the pool of cGMP by activating guanylyl cyclase, setting the stage for the activation of cGMP-dependent pathways that can lead to the enhancement of V3R 6 function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase to increase cAMP levels, which in turn activates protein kinase A (PKA). PKA phosphorylates and enhances the activity of V3R 6. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol activates beta-adrenergic receptors, leading to elevated cAMP and subsequent activation of PKA, which may phosphorylate and enhance the activity of V3R 6. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4, increasing cAMP levels, and thus, enhancing PKA activity which can lead to the activation of V3R 6. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX inhibits various phosphodiesterases, increasing cAMP levels, which can activate PKA and enhance the functional activity of V3R 6 through phosphorylation. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine acts on adrenergic receptors to increase cAMP production, which activates PKA, leading to the phosphorylation and potential activation of V3R 6. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2, via EP2 and EP4 receptors, increases cAMP levels and activates PKA, which may result in the phosphorylation and enhanced activity of V3R 6. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin activates the JNK pathway, which can influence transcription factors and other proteins to create a signaling state that enhances the activity of V3R 6. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), and PKC-mediated signaling can lead to phosphorylation events that enhance the activity of V3R 6. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil inhibits PDE5, raising cGMP levels, which could activate cGMP-dependent protein kinases and subsequently enhance V3R 6 activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits PDE5, increasing cGMP concentration and potentially leading to the activation of cGMP-dependent kinases that enhance V3R 6 activity. | ||||||